82 related articles for article (PubMed ID: 8818660)
1. ERBB2 and chromosome 17 centromere studies of ovarian cancer by fluorescence in situ hybridization.
Young SR; Liu WH; Brock JA; Smith ST
Genes Chromosomes Cancer; 1996 Jun; 16(2):130-7. PubMed ID: 8818660
[TBL] [Abstract][Full Text] [Related]
2. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma.
Afify AM; Werness BA; Mark HF
Exp Mol Pathol; 1999 Jun; 66(2):163-9. PubMed ID: 10409445
[TBL] [Abstract][Full Text] [Related]
4. Centromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?
Petroni S; Addati T; Mattioli E; Caponio MA; Quero C; Rubini V; Giotta F; Simone G
Arch Pathol Lab Med; 2012 Sep; 136(9):993-1000. PubMed ID: 22938586
[TBL] [Abstract][Full Text] [Related]
5. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.
Mark HF; Feldman D; Das S; Kye H; Mark S; Sun CL; Samy M
Exp Mol Pathol; 1999 Jun; 66(2):170-8. PubMed ID: 10409446
[TBL] [Abstract][Full Text] [Related]
6. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
[TBL] [Abstract][Full Text] [Related]
7. Detection of Her2/neu, c-MYC and ZNF217 gene amplification during breast cancer progression using fluorescence in situ hybridization.
Shimada M; Imura J; Kozaki T; Fujimori T; Asakawa S; Shimizu N; Kawaguchi R
Oncol Rep; 2005 Apr; 13(4):633-41. PubMed ID: 15756435
[TBL] [Abstract][Full Text] [Related]
8. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
[TBL] [Abstract][Full Text] [Related]
9. Detection of numerical chromosome anomalies in interphase cells of ovarian carcinomas using fluorescence in situ hybridization.
Brock JA; Liu WH; Smith ST; Young SR
Genes Chromosomes Cancer; 1996 Jun; 16(2):120-9. PubMed ID: 8818659
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
11. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.
Mezzelani A; Alasio L; Bartoli C; Bonora MG; Pierotti MA; Rilke F; Pilotti S
Br J Cancer; 1999 May; 80(3-4):519-25. PubMed ID: 10408862
[TBL] [Abstract][Full Text] [Related]
12. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
13. Assessment of chromosomal trisomies in prostate cancer using fluorescent in situ hybridization.
Mark HF; Feldman D; Das S; Samy M; Sun CL; Mark S
Exp Mol Pathol; 1999 Oct; 67(2):109-17. PubMed ID: 10527762
[TBL] [Abstract][Full Text] [Related]
14. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
[TBL] [Abstract][Full Text] [Related]
15. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
Bartlett JM; Campbell FM; Mallon EA
Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu oncogene amplification and chromosome 17 aneusomy in endometrial carcinoma: correlation with oncoprotein expression and conventional pathological parameters.
Cianciulli AM; Guadagni F; Marzano R; Benevolo M; Merola R; Giannarelli D; Marandino F; Vocaturo G; Mariani L; Mottolese M
J Exp Clin Cancer Res; 2003 Jun; 22(2):265-71. PubMed ID: 12866577
[TBL] [Abstract][Full Text] [Related]
17. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
Santin AD; Bellone S; Van Stedum S; Bushen W; Palmieri M; Siegel ER; De Las Casas LE; Roman JJ; Burnett A; Pecorelli S
Cancer; 2005 Oct; 104(7):1391-7. PubMed ID: 16116605
[TBL] [Abstract][Full Text] [Related]
18. Identification of HER-2/neu oncogene amplification by fluorescence in situ hybridization in stage I endometrial carcinoma.
Riben MW; Malfetano JH; Nazeer T; Muraca PJ; Ambros RA; Ross JS
Mod Pathol; 1997 Aug; 10(8):823-31. PubMed ID: 9267826
[TBL] [Abstract][Full Text] [Related]
19. Trisomy 8 in stage I and stage III ovarian cancer detected by fluorescence in situ hybridization.
Mark HF; Afify AM; Werness BA; Das S; Mark S; Samy M
Exp Mol Pathol; 1999 Apr; 66(1):76-81. PubMed ID: 10331967
[TBL] [Abstract][Full Text] [Related]
20. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.
Liu HL; Gandour-Edwards R; Lara PN; de Vere White R; LaSalle JM
Cancer J; 2001; 7(5):395-403. PubMed ID: 11693898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
